trial · primary record
Elranatamab
Multiple Myeloma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1060 |
| Primary completion | 2033-10-03 |
| Primary endpoint | Part 1 Dose Limiting Toxicity |
| Registry ID | NCT05623020 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:08.727Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05623020
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.